Table 1

Demographic data and baseline clinical, gait and occupational results for each treatment group

PlaceboEtanercept
Male, N (%)17 (85.0)15 (75.0)
Mean (SD) age (years)39.4 (10.1)40.8 (9.7)
Median (range) disease duration (months)240 (7–360)132 (25–540)
Mean (SD) AS-WIS14.18 (3.57)15.32 (3.55)
AS-WIS, N (%)
 Low (<11)1 (5.0%)0 (0.0%)
 Moderate (11–18)13 (65.0%)13 (65.0%)
 High (19–20)6 (30.0%)7 (35.0%)
Mean (SD) BASDAI5.46 (1.74)6.05 (1.71)
Mean (SD) BASFI5.27 (1.81)5.60 (1.98)
Mean (SD) ASQoL10.07 (3.97)11.76 (3.06)
Mean (SD) HAQ-DI0.813 (0.469)0.925 (0.452)
Mean (SD) gait velocity* (cm/s)112.57 (18.97)108.79 (27.23)
Mean (SD) step length* (cm)62.15 (7.60)63.27 (9.98)
Non-manual work, N (%)13 (65.0%)11 (55.0%)
Manual work, N (%)7 (35.0%)9 (45.0%)
Mean (SD) hours worked in first week36.9 (14.1)28.4 (9.9)
  • Ankylosing Spondylitis Work Instability Score (AS-WIS) range 0–20; Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) range 0–10; Bath Ankylosing Spondylitis Functional Index (BASFI) range 0–10; Ankylosing Spondylitis Quality of Life instrument (ASQoL) range 0–18; Disability Index of the Stanford Health Assessment Questionnaire (HAQ-DI) range 0–3.

  • * Both groups n=16.

  • Placebo n=11, etanercept n=16.